Daiichi Sankyo appoints Antoine Yver as Global Head, Oncology Research and Development

He will lead all global R&D across the oncology therapeutic area

Daiichi Sankyo has hired Antoine Yver as Global Head, Oncology Research and Development.

In this newly created role, Dr Yver will report to Glenn Gormley, Senior Executive Officer and Global Head, Research & Development, Daiichi Sankyo Co and Chairman of the Board and President, Daiichi Sankyo Inc, and will have responsibility for leading all of the global research and development across the oncology therapeutic area including external investments, internal pipeline decisions, and resourcing requirements.

Dr Yver joins Daiichi Sankyo from AstraZeneca, where most recently he was Senior Vice President and Head of Oncology, Global Medicines Development, and Global Medicines Development China Lead across all therapeutic areas.

Prior to joining AstraZeneca in 2009, he held several international oncology drug development positions at Merck/Schering-Plough, Johnson & Johnson and Rhône-Poulenc Rorer/Aventis.

Companies